Home » AMYLIN'S EXENATIDE LAR PRICING IN HALF OF STOCK'S VALUE
AMYLIN'S EXENATIDE LAR PRICING IN HALF OF STOCK'S VALUE
Merrill Lynch upgraded Amylin Pharmaceuticals to "neutral" from "sell," citing more reasonable share prices, but said it continues to be wary of risks related to experimental drug exenatide LAR.
Forbes (http://www.forbes.com/technology/sciences/2006/02/13/amylin-exenatide-0213markets10.html?partner=rss)
(http://www.bloomberg.com/apps/news?pid=10000102&sid=aYW4iYmkPTMc&refer=uk)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May